In addition to mutations in Ras, the MAPK pathway can also become activated due to mutations in the Ras-binding kinase rapidly accelerated fibrosarcoma (Raf) or to inactivating mutations in negative regulators of MAPK such as neurofibromin 1 (NF1) [56]. The gene discussed is NF1; the disease is fibrosarcoma.